舍曲林对非透析慢性肾脏病患者抑郁症状的影响:CAST随机临床试验
CAST随机双盲安慰剂对照试验纳入201例3-5期非透析慢性肾脏病合并重度抑郁症患者,比较舍曲林与安慰剂治疗12周的效果。结果显示舍曲林组与安慰剂组QIDS-C16评分变化无显著差异(-4.1 vs -4.2,组间差异0.1,95%CI -1.1至1.3,P=0.82),但舍曲林组恶心或呕吐及腹泻发生率更高。结论不支持使用舍曲林治疗此类患者的抑郁症。
要点
- 舍曲林组与安慰剂组12周QIDS-C16评分变化无显著差异(-4.1 vs -4.2,组间差异0.1,P=0.82)。
- 舍曲林组恶心或呕吐发生率22.7% vs 安慰剂组10.4%(组间差异12.3%,P=0.03)。
- 舍曲林组腹泻发生率13.4% vs 安慰剂组3.1%(组间差异10.3%,P=0.02)。
核心结论
- 在非透析慢性肾脏病合并重度抑郁症患者中,与安慰剂相比,舍曲林治疗12周未显著改善抑郁症状。
- 这些发现不支持使用舍曲林治疗非透析慢性肾脏病患者的抑郁症。
研究设计与样本
- CAST为随机双盲安慰剂对照试验,在美国3个医疗中心纳入201例3、4或5期非透析慢性肾脏病患者,使用简易神经精神访谈确立重度抑郁症。
- 首例参与者于2010年3月随机化,末次门诊访视于2016年11月。
- 经过1周安慰剂导入后,参与者随机接受舍曲林(n=102)初始剂量50 mg/d,根据耐受性和反应上调至最大200 mg/d,或匹配安慰剂(n=99),疗程12周。
主要发现
- 共201例患者随机化,平均(SD)年龄58.2(13.2)岁,女性占27%。
- 主要分析纳入193例随机化后至少有一次结局评估的患者;舍曲林组基线QIDS-C16平均(SD)评分为14.0(2.4)(n=97),安慰剂组为14.1(2.4)(n=96)。
- 中位参与时间为12.0周,中位达到剂量为150 mg/d,两组间无显著差异。
- QIDS-C16评分在舍曲林组变化-4.1,在安慰剂组变化-4.2,组间差异0.1(95%CI -1.1至1.3;P=0.82)。
- 患者报告的肾脏病生活质量简表总体健康变化中位数舍曲林组为0,安慰剂组为0,组间差异0(95%CI -10.0至0;P=0.61),无显著组间差异。
关键数值与推荐
- 主要结局为12周时QIDS-C16评估的抑郁症状严重程度较基线的改善,评分范围0-27,最小临床重要差异为2分。
- 次要结局包括生活质量改善(肾脏病生活质量简表短表,评分范围0-100,分数越高表示生活质量越好)和不良事件。
临床怎么用
- 原文结论指出,这些发现不支持使用舍曲林治疗非透析慢性肾脏病患者的抑郁症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Major depressive disorder (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morbidity and mortality. The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unknown. OBJECTIVE: To determine whether treatment with sertraline improves depressive symptoms in patients with CKD and MDD. DESIGN, SETTING, AND PARTICIPANTS: The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with stage 3, 4, or 5 non-dialysis-dependent CKD, who were enrolled at 3 US medical centers. The Mini Neuropsychiatric Interview was used to establish MDD. The first participant was randomized in March 2010 and the last clinic visit occurred in November 2016. INTERVENTIONS: After a 1-week placebo run-in, participants were randomized to sertraline (n = 102) for 12 weeks at an initial dose of 50 mg/d (escalated to a maximum dose of 200 mg/d based on tolerability and response) or matching placebo (n = 99). MAIN OUTCOMES AND MEASURES: The primary outcome was improvement in depressive symptom severity from baseline to 12 weeks determined by the 16-item Quick Inventory of Depression Symptomatology-Clinician Rated (QIDS-C16) (score range, 0-27; minimal clinically important difference, 2 points). Secondary outcomes included improvement in quality of life (Kidney Disease Quality of Life Survey-Short Form; score range, 0-100; higher scores indicate more favorable quality of life) and adverse events. RESULTS: There were 201 patients (mean [SD] age, 58.2 [13.2] years; 27% female) randomized. The primary analysis included 193 patients who had at least 1 outcome assessment after randomization. The mean (SD) baseline QIDS-C16 score was 14.0 (2.4) in the sertraline group (n = 97) and 14.1 (2.4) in the placebo group (n = 96). The median participation time was 12.0 weeks and the median achieved dose was 150 mg/d, which was not significantly different between the groups. The QIDS-C16 score changed by -4.1 in the sertraline group and by -4.2 in the placebo group (between-group difference, 0.1 [95% CI, -1.1 to 1.3]; P = .82). There was no significant between-group difference in change in patient-reported overall health on the Kidney Disease Quality of Life Survey (median score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [95% CI, -10.0 to 0]; P = .61). Nausea or vomiting occurred more frequently in the sertraline vs placebo group (22.7% vs 10.4%, respectively; between-group difference, 12.3% [95% CI, 1.9% to 22.6%], P = .03), as well as diarrhea (13.4% vs 3.1%; between-group difference, 10.3% [95% CI, 2.7% to 17.9%], P = .02). CONCLUSIONS AND RELEVANCE: Among patients with non-dialysis-dependent CKD and MDD, treatment with sertraline compared with placebo for 12 weeks did not significantly improve depressive symptoms. These findings do not support the use of sertraline to treat MDD in patients with non-dialysis-dependent CKD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00946998.
引用
- Hedayati SS, Gregg LP, Carmody T, et al. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. JAMA. 2017. PMID: 29101402. doi:10.1001/jama.2017.17131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。